Background: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is considered a potential therapy for long-term survival, used as post-remission therapy in leukemias whose response to earlier treatments was not effective. Relapse and associated disease progression are some of the main complications after the transplantation period that may lead to uncertain clinical endings. Transplantation monitorin...